ArticleOncology letters2025
miRNA‑22‑3p inhibits cell viability and metastasis of nasopharyngeal carcinoma by targeting FOXP1.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of miRNA‑214‑3p in cancer (Review).Oncology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) is a malignant tumor with a high incidence rate in certain regions. MicroRNA (miRNA/miR)-22-3p is implicated in the regulation of tumorigenesis and progression. However, the biological role of miRNA-22-3p in the progression of NPC remains unclear. The present study aimed to assess the effects of miRNA-22-3p overexpression on the cell viability and migration of NPC cells. The cell viability and migration of HK-1 cells was evaluated using Transwell, wound healing and Cell Counting Kit-8 assays. To assess the epithelial-mesenchymal transition ability of NPC cells, the expression of E-cadherin, vimentin and N-cadherin was evaluated using western blot analysis. The results revealed expression of miRNA-22-3p was significantly decreased in NPC tissues compared with para-cancerous tissues. Decreased expression of miRNA-22-3p was also observed in NPC cell lines (C666-1 and HK-1). The overexpression of miRNA-22-3p reduced HK-1 cell viability and migration. In addition, a dual luciferase reporter assay revealed that miRNA-22-3p functioned as a molecular sponge for forkhead box protein 1 (FOXP1). Notably, FOXP1 overexpression counteracted the suppressive effects induced by transfection with miRNA-22-3p mimic on HK-1 cell viability and migration. Therefore, these data indicate that miRNA-22-3p may be a clinically valuable biomarker for the therapy of NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.